



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Walter Dunn, M.D., Ph.D.**

Committee: **Psychopharmacologic Drugs Advisory Committee**

Meeting Date: **June 17, 2022**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On June 17, 2022, the committee will discuss supplemental new drug applications 210793-s008 and 207318-s011, efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP), I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	Stock holdings in four competing firms (b) (6) _____).	Aggregate value: \$17,500 - \$37,500
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/
Signature

5/31/2022
Date